JAV Javelin Pharmaceuticals

Explanatory Notes   

Introduction

   This Amendment No. 2 to Schedule 13D ("Amendment No. 2 to Schedule 13D"), amends and restates Amendment No. 1 to Schedule 13D filed on April 14, 2010 by Millenco LLC, Integrated Core Strategies (US) LLC, ICS Opportunities, Ltd., Millennium International Management LP, Millennium International Management GP LLC, Millennium Management LLC and Israel A. Englander ("Amendment No. 1 to Schedule 13D"), relating to their beneficial ownership of the common stock, par value $0.001 per share (the "Common Stock"), of Javelin Pharmaceuticals, Inc., a Delaware corporation (the "Issuer").

   This Amendment No. 2 to Schedule 13D is being filed to report a material change in the number of shares beneficially owned or deemed to be beneficially owned by ICS Opportunities, Ltd., Millennium International Management LP, Millennium International Management GP LLC, Millennium Management LLC and Israel A. Englander, as the case may be, since the filing of Amendment No. 1 to Schedule 13D.

Item 1.      Security and Issuer.

   The name of the Issuer is Javelin Pharmaceuticals, Inc. The address of the Issuer’s principal executive offices is 125 CambridgePark Drive, Cambridge, Massachusetts 02140. This Amendment No. 2 to Schedule 13D relates to the Issuer’s Common Stock.

Item 2.      Identity and Background.

   (a)-(c), (f)  This Amendment No. 2 to Schedule 13D is being filed by ICS Opportunities, Ltd., an exempted limited company organized under the laws of the Cayman Islands ("ICS Opportunities").

   Millennium International Management LP, a Delaware limited partnership ("Millennium International Management"), is the investment manager to ICS Opportunities and may be deemed to have shared voting control and investment discretion over securities owned by ICS Opportunities.

   Millennium International Management GP LLC, a Delaware limited liability company ("Millennium International Management GP"), is the general partner of Millennium International Management and may also be deemed to have shared voting control and investment discretion over securities owned by ICS Opportunities.

   Millennium Management LLC, a Delaware limited liability company ("Millennium Management"), is the general partner of the 100% shareholder of ICS Opportunities and may be deemed to have shared voting control and investment discretion over securities owned by ICS Opportunities.

   Israel A. Englander, a United States citizen ("Mr. Englander"), is the managing member of Millennium International Management GP and of Millennium Management and consequently may also be deemed to have shared voting control and investment discretion over securities owned by ICS Opportunities.

   The foregoing should not be construed in and of itself as an admission by Millennium International Management, Millennium International Management GP, Millennium Management or Mr. Englander as to beneficial ownership of the securities owned by ICS Opportunities.

   ICS Opportunities, Millennium International Management, Millennium International Management GP, Millennium Management and Mr. Englander will be collectively referred to as the reporting persons ("Reporting Persons") in this Amendment No. 2 to Schedule 13D.

   The business address for ICS Opportunities is c/o Millennium International Management LP, 666 Fifth Avenue, New York, New York 10103. The business address for Millennium International Management is c/o Millennium International Management GP LLC, 666 Fifth Avenue, New York, NY 10103. The business address for Millennium International Management GP and Millennium Management is 666 Fifth Avenue, New York, New York 10103. The business address for Mr. Englander is c/o Millennium Management LLC, 666 Fifth Avenue, New York, New York 10103.

   (d)  During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

   (e)  On December 1, 2005, Millennium Management and Mr. Englander, together with Millennium Partners, L.P. ("Millennium Partners") and certain related persons and entities, entered into settlements with the Securities and Exchange Commission ("SEC") and the Attorney General of the State of New York (the "NYAG") relating to allegations that Millennium Partners had engaged in a pattern of deceptive "market timing" of mutual fund shares in years prior to 2004 and, in the case of the settlement with the NYAG only, had failed to take adequate steps to prevent a trader from engaging in mutual fund "late trading" in violation of firm policy. The parties neither admitted nor denied the allegations or findings (except as to jurisdiction) but consented to the entry of findings. The SEC proceedings are In the Matter of Millennium Partners, L.P., et al. Securities Act Release No. 8639 (December 1, 2005), available at www.sec.gov. Contemporaneously, the NYAG issued an Assurance of Discontinuance relating to the claims and findings of that office.

   Neither the Reporting Persons nor any other party admitted or denied any of the allegations or findings in these matters. The remedies included disgorgement by the entities of approximately $148 million of mutual fund trading profits, civil penalties aggregating approximately $32.15 million (with approximately $30 million being paid by Mr. Englander), an administrative order to cease and desist from violations of the antifraud provisions of the Securities Act of 1933 and the Securities Exchange Act of 1934 (the "Exchange Act"), and prophylactic relief.

Item 3.      Source and Amount of Funds or Other Consideration.

   The amount of funds used to purchase the 6,322,289 shares of the Issuer’s Common Stock held by ICS Opportunities was approximately $11,440,949, calculated on an average cost basis (excluding brokerage commissions) by account. ICS Opportunities effects purchases of securities primarily through margin accounts maintained for it with prime brokers, which may extend margin credit to ICS Opportunities, as and when required to open or carry positions in the margin accounts, subject to applicable margin regulations, stock exchange rules and the prime broker’s credit policies. In such instances, the positions held in the margin accounts are pledged as collateral security for the repayment of debit balances in the accounts.

Item 4.       Purpose of Transaction.

   The Reporting Persons are engaged in the investment business, and in the course of that business employ the services of a number of portfolio managers, each of whom independently employs a separate and distinct trading strategy. A portion of the securities of the Issuer held by the Reporting Persons may be managed by portfolio managers who engage in event-, risk- or merger-arbitrage or fundamental strategies.

   In pursuing their business, some of the Reporting Persons’ portfolio managers analyze the operations, capital structure and markets of companies, including the Issuer, on a continuous basis, through analysis of documentation and discussions with knowledgeable industry and market observers and with representatives of such companies (often at the invitation of management). (Other portfolio managers, who may also have long or short positions in securities of the Issuer from time to time, trade pursuant to quantitative or other strategies that do not involve such analyses and discussions.) From time to time, one or more of the portfolio managers may hold discussions with third parties or with management of issuers (including the Issuer) in which the portfolio managers may suggest or take a position with respect to potential changes in the operations, management or capital structure of such companies as a means of enhancing shareholder value. Such suggestions or positions may relate to one or more transactions of the type specified in clauses (a) through (j) of Item 4 of Schedule 13D of the Exchange Act, including, without limitation, such matters as disposing of or selling all or a portion of the company or acquiring another company or business, changing operating or marketing strategies, adopting or not adopting certain types of anti-takeover measures and restructuring the Issuer’s capitalization or dividend policy.

   The Reporting Persons are evaluating the binding offer that the Issuer received from Hospira, Inc. to acquire all of the Issuer’s outstanding shares in a cash tender offer at a price of $2.20 per share. The Reporting Persons believe that although this new offer is an improvement to the existing merger with Myriad Pharmaceuticals, Inc., the $2.20 per share price in the binding offer does not maximize value to the shareholders of the Issuer.

   Except as set forth above, the Reporting Persons do not have any present plans or proposals that relate to or would result in any of the actions required to be described in Item 4 of this Amendment No. 2 to Schedule 13D. Each of the Reporting Persons may, at any time, review or reconsider its position with respect to the Issuer and formulate plans or proposals with respect to any of such matters, but has no present intention of doing so.

Item 5.      Interest in Securities of the Issuer.

   (a)  As of the date of this Amendment No. 2 to Schedule 13D, ICS Opportunities is the beneficial owner of 6,322,289 shares or approximately 9.8% of the Issuer’s outstanding Common Stock. The calculation of the foregoing percentage is on the basis of 64,368,371 shares of Common Stock outstanding as of March 4, 2010, as per the Issuer’s Form 10-K dated March 8, 2010.

   Millennium International Management, as the investment manager to ICS Opportunities, may be deemed to have shared voting control and investment discretion over securities owned by ICS Opportunities.

   Millennium International Management GP, as the general partner of Millennium International Management, may also be deemed to have shared voting control and investment discretion over securities owned by ICS Opportunities.

   Millennium Management, as the general partner of the 100% shareholder of ICS Opportunities, may be deemed to have shared voting control and investment discretion over securities owned by ICS Opportunities.

   Mr. Englander, as the managing member of Millennium International Management GP and of Millennium Management, may also be deemed to be the beneficial owner of any securities owned by ICS Opportunities.

   The foregoing should not be construed in and of itself as an admission by Millennium International Management, Millennium International Management GP, Millennium Management or Mr. Englander as to beneficial ownership of the securities owned by ICS Opportunities.

   (b)  ICS Opportunities holds shared power to vote and to dispose of the 6,322,289 shares of the Issuer’s Common Stock described in (a) above. Millennium International Management, Millennium International Management GP, Millennium Management and Mr. Englander may each be deemed to hold shared power to vote and to dispose of the 6,322,289 shares of the Issuer’s Common Stock described in (a) above. The foregoing should not be construed in and of itself as an admission by Millennium International Management, Millennium International Management GP, Millennium Management or Mr. Englander as to beneficial ownership of the securities owned by ICS Opportunities.

   (c)  Transactions in the Issuer’s Common Stock since April 13, 2010, the date of Amendment No. 1 to Schedule 13D: Schedule A annexed hereto lists all transactions in the Issuer’s Common Stock effected by the Reporting Persons since April 13, 2010, the date of Amendment No. 1 to Schedule 13D. All such transactions in the Issuer’s Common Stock were effected by ICS Opportunities in the open market.

   (d)  No person other than the Reporting Persons is known to have the right to receive, or the power to direct the receipt of, dividends from, or proceeds from the sale of, the shares of Common Stock reported in this Amendment No. 2 to Schedule 13D.

Item 6.      Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

   In connection with arrangements with ICS Opportunities’ prime brokers, such prime brokers are permitted to lend securities in ICS Opportunities’ accounts to the extent permitted by debit balances in such accounts. ICS Opportunities generally will not have any knowledge of the specific loans made by such prime brokers. In the ordinary course of business, ICS Opportunities (or its prime brokers), may borrow securities to satisfy delivery obligations arising from short sales. Shares lent by ICS Opportunities’ prime brokers, may not be able to be recalled in advance of an applicable record date and thus, such loaned shares may not be able to be voted by ICS Opportunities.

   There are no other contracts, arrangements, understandings or relationships among the Reporting Persons, or between the Reporting Persons and any other person, with respect to the securities of the Issuer.

Item 7.      Material to Be Filed as Exhibits.

   Exhibit I:  Joint Filing Agreement, dated as of April 15, 2010, by and among ICS Opportunities, Ltd., Millennium International Management LP, Millennium International Management GP LLC, Millennium Management LLC and Israel A. Englander.

SIGNATURE

   After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: April 15, 2010

ICS OPPORTUNITIES, LTD. By: Millennium International Management LP,        as Investment Manager

By: /s/ David Nolan

Name: David Nolan Title:  Co-President

MILLENNIUM INTERNATIONAL MANAGEMENT LP

By: /s/David Nolan

Name: David Nolan Title:  Co-President

MILLENNIUM INTERNATIONAL MANAGEMENT GP LLC

By: /s/David Nolan

Name: David Nolan Title:  Executive Vice President

MILLENNIUM MANAGEMENT LLC

By: /s/David Nolan

Name: David Nolan Title:  Co-President

/s/ Israel A. Englander by David Nolan pursuant to Power of Attorney filed with the SEC on June 6, 2005

Israel A. Englander

---

EXHIBIT I

JOINT FILING AGREEMENT

    This will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.001 per share, of Javelin Pharmaceuticals, Inc., a Delaware corporation, is being filed and all amendments thereto will be filed, on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

Dated: April 15, 2010

ICS OPPORTUNITIES, LTD. By: Millennium International Management LP,        as Investment Manager

By: /s/ David Nolan

Name: David Nolan Title:  Co-President

MILLENNIUM INTERNATIONAL MANAGEMENT LP

By: /s/David Nolan

Name: David Nolan Title:  Co-President

MILLENNIUM INTERNATIONAL MANAGEMENT GP LLC

By: /s/David Nolan

Name: David Nolan Title:  Executive Vice President

MILLENNIUM MANAGEMENT LLC

By: /s/David Nolan

Name: David Nolan Title:  Co-President

/s/ Israel A. Englander by David Nolan pursuant to Power of Attorney filed with the SEC on June 6, 2005

Israel A. Englander

---

Schedule A

Transactions in the Issuer’s Common Stock since April 13, 2010, the date of Amendment No. 1 to Schedule 13D:

Date of Transaction	Quantity Purchased (Sold)	Price Per Share $
4/15/2010	1,000	2.17
4/15/2010	1,800	2.17
4/15/2010	3,400	2.17
4/15/2010	1,200	2.17
4/15/2010	1,000	2.17
4/15/2010	4,000	2.17
4/15/2010	1,000	2.17
4/15/2010	45	2.17
4/15/2010	100	2.17
4/15/2010	1,700	2.17
4/15/2010	1,600	2.17
4/15/2010	5,000	2.17
4/15/2010	100	2.17
4/15/2010	1,500	2.17
4/15/2010	3,500	2.17
4/15/2010	100	2.17
4/15/2010	900	2.17
4/15/2010	4,100	2.17
4/15/2010	300	2.17
4/15/2010	3,700	2.17
4/15/2010	100	2.17
4/15/2010	300	2.17
4/15/2010	1,659	2.17
4/15/2010	200	2.17
4/15/2010	100	2.17
4/15/2010	100	2.17
4/15/2010	400	2.17
4/15/2010	100	2.17
4/15/2010	996	2.17
4/15/2010	400	2.17
4/15/2010	1,104	2.17
4/15/2010	300	2.17
4/15/2010	200	2.17
4/15/2010	500	2.17
4/15/2010	41	2.17
4/15/2010	1,359	2.17
4/15/2010	400	2.17
4/15/2010	286	2.17
4/15/2010	114	2.17
4/15/2010	2,800	2.17
4/15/2010	200	2.17
4/15/2010	1,200	2.17
4/15/2010	100	2.17
4/15/2010	900	2.17
4/15/2010	200	2.17
4/15/2010	500	2.17
4/15/2010	1,000	2.17
4/15/2010	1,000	2.17
4/15/2010	1,000	2.17
4/15/2010	1,300	2.17
4/15/2010	3,000	2.17
4/15/2010	2,000	2.17
4/15/2010	1,000	2.17
4/15/2010	1,000	2.17
4/15/2010	100	2.17
4/15/2010	2,500	2.17
4/15/2010	800	2.17
4/15/2010	200	2.17
4/15/2010	100	2.17
4/15/2010	300	2.17
4/15/2010	1,300	2.17
4/15/2010	200	2.17
4/15/2010	1,300	2.17
4/15/2010	1,000	2.17
4/15/2010	500	2.17
4/15/2010	18,400	2.17
4/15/2010	1,000	2.17
4/15/2010	1,400	2.17
4/15/2010	16,000	2.17
4/15/2010	300	2.17
4/15/2010	100	2.17
4/15/2010	1,000	2.17
4/15/2010	900	2.17
4/15/2010	1,000	2.17
4/15/2010	1,000	2.17
4/15/2010	1,400	2.17
4/15/2010	200	2.17
4/15/2010	100	2.17
4/15/2010	100	2.17
4/15/2010	4,000	2.17
4/15/2010	500	2.17
4/15/2010	2,500	2.17
4/15/2010	1,500	2.17
4/15/2010	1,000	2.17
4/15/2010	4,900	2.17
4/15/2010	2,000	2.17
4/15/2010	3,000	2.17
4/15/2010	1,300	2.17
4/15/2010	1,300	2.17
4/15/2010	3,000	2.17
4/15/2010	100	2.17
4/15/2010	2,500	2.17
4/15/2010	1,000	2.17
4/15/2010	1,300	2.17
4/15/2010	1,300	2.17
4/15/2010	800	2.17
4/15/2010	500	2.17
4/15/2010	1,000	2.17
4/15/2010	1,000	2.17
4/15/2010	1,000	2.17
4/15/2010	300	2.17
4/15/2010	100	2.17
4/15/2010	4,700	2.17
4/15/2010	100	2.17
4/15/2010	100	2.17
4/15/2010	100	2.17
4/15/2010	100	2.17
4/15/2010	300	2.17
4/15/2010	100	2.17
4/15/2010	100	2.17
4/15/2010	100	2.17
4/15/2010	39	2.17
4/15/2010	100	2.17
4/15/2010	2,000	2.17
4/15/2010	300	2.17
4/15/2010	4,000	2.17
4/15/2010	100	2.17
4/15/2010	100	2.17
4/15/2010	30	2.17
4/15/2010	3,000	2.17
4/15/2010	500	2.17
4/15/2010	200	2.17
4/15/2010	1,000	2.17
4/15/2010	1,000	2.17
4/15/2010	2,500	2.17
4/15/2010	2,200	2.17
4/15/2010	10,000	2.17
4/15/2010	2,800	2.17
4/15/2010	9,799	2.17
4/15/2010	800	2.17
4/15/2010	1,527	2.17
4/15/2010	5,017	2.17
4/15/2010	5,000	2.17
4/15/2010	100	2.17
4/15/2010	100	2.17
4/15/2010	100	2.17
4/15/2010	1,849	2.17
4/15/2010	1,000	2.17
4/15/2010	1,149	2.17
4/15/2010	15	2.17
4/15/2010	2,000	2.17
4/15/2010	3,200	2.17
4/15/2010	200	2.17
4/15/2010	1,375	2.17
4/15/2010	3,800	2.17
4/15/2010	100	2.17
4/15/2010	767	2.17
4/15/2010	1,600	2.17
4/15/2010	1,600	2.17
4/15/2010	1,000	2.17
4/15/2010	12,633	2.17
4/15/2010	9,700	2.17
4/15/2010	970	2.17
4/15/2010	700	2.17
4/15/2010	100	2.17
4/15/2010	100	2.17
4/15/2010	900	2.17
4/15/2010	200	2.17
4/15/2010	1,000	2.17
4/15/2010	100	2.17
4/15/2010	72,230	2.17
4/15/2010	8,968	2.17
4/15/2010	720	2.17
4/15/2010	100	2.17
4/15/2010	100	2.17
4/15/2010	100	2.17
4/15/2010	100	2.17
4/15/2010	3,223	2.17
4/15/2010	10,189	2.17
4/15/2010	100	2.17
4/15/2010	100	2.17
4/15/2010	100	2.17
4/15/2010	100	2.17
4/15/2010	100	2.17
4/15/2010	100	2.17
4/15/2010	100	2.17
4/15/2010	100	2.17
4/15/2010	100	2.17
4/15/2010	100	2.17
4/15/2010	13,900	2.17
4/15/2010	100	2.17
4/15/2010	100	2.17
4/15/2010	100	2.17
4/15/2010	100	2.17
4/15/2010	3,000	2.17
4/15/2010	100	2.17
4/15/2010	1,900	2.17
4/15/2010	200	2.17
4/15/2010	100	2.17
4/15/2010	100	2.17
4/15/2010	100	2.17
4/15/2010	100	2.17
4/15/2010	800	2.17
4/15/2010	500	2.17
4/15/2010	3,000	2.17
4/15/2010	100	2.17
4/15/2010	2,900	2.17
4/15/2010	5,000	2.17
4/15/2010	5,000	2.17
4/15/2010	500	2.17
4/15/2010	1,500	2.17
4/15/2010	2,000	2.17
4/15/2010	1,000	2.17
4/15/2010	500	2.17
4/15/2010	100	2.17
4/15/2010	100	2.17
4/15/2010	10,000	2.17
4/15/2010	100	2.17
4/15/2010	16,100	2.17
4/15/2010	100	2.17
4/15/2010	1,700	2.17
4/15/2010	100	2.17
4/15/2010	1,500	2.17
4/15/2010	1,000	2.17
4/15/2010	100	2.17
4/15/2010	1,000	2.17
4/15/2010	3,000	2.17
4/15/2010	100	2.17
4/15/2010	59	2.17
4/15/2010	41	2.17
4/15/2010	100	2.17
4/15/2010	5,000	2.17
4/15/2010	1,000	2.17
4/15/2010	2,000	2.18
4/15/2010	100	2.17
4/15/2010	1,000	2.18
4/15/2010	100	2.17
4/15/2010	1,000	2.18
4/15/2010	100	2.17
4/15/2010	500	2.18
4/15/2010	5,000	2.17
4/15/2010	2,000	2.18
4/15/2010	12,000	2.18
4/15/2010	200	2.17
4/15/2010	1,000	2.18
4/15/2010	2,000	2.18
4/15/2010	200	2.17
4/15/2010	100	2.18
4/15/2010	1,000	2.18
4/15/2010	2,450	2.18
4/15/2010	200	2.17
4/15/2010	300	2.18
4/15/2010	1,000	2.17
4/15/2010	4,000	2.18
4/15/2010	1,000	2.17
4/15/2010	500	2.18
4/15/2010	1,000	2.17
4/15/2010	200	2.17
4/15/2010	200	2.17
4/15/2010	1,000	2.18
4/15/2010	100	2.18
4/15/2010	100	2.18
4/15/2010	100	2.18
4/15/2010	100	2.18
4/15/2010	100	2.18
4/15/2010	200	2.18
4/15/2010	13,000	2.18
4/15/2010	2,000	2.18
4/15/2010	1,000	2.18
4/15/2010	1,000	2.18
4/15/2010	1,000	2.18
4/15/2010	100	2.1775
4/15/2010	500	2.18
4/15/2010	800	2.18
4/15/2010	9,200	2.18
4/15/2010	200	2.18
4/15/2010	800	2.18
4/15/2010	2,500	2.18
4/15/2010	1,000	2.18
4/15/2010	12,100	2.18
4/15/2010	500	2.18
4/15/2010	5,000	2.18
4/15/2010	100	2.18
4/15/2010	250	2.18
4/15/2010	500	2.18
4/15/2010	200	2.18
4/15/2010	1,000	2.18
4/15/2010	400	2.18
4/15/2010	5,550	2.18
4/15/2010	100	2.18
4/15/2010	1,000	2.18
4/15/2010	1,000	2.18
4/15/2010	1,000	2.18
4/15/2010	100	2.18
4/15/2010	100	2.18
4/15/2010	1,400	2.18
4/15/2010	150	2.18
4/15/2010	3,278	2.18
4/15/2010	1,000	2.18
4/15/2010	100	2.18
4/15/2010	100	2.18
4/15/2010	29	2.18
4/15/2010	100	2.18
4/15/2010	100	2.18
4/15/2010	100	2.18
4/15/2010	800	2.18
4/15/2010	71	2.18
4/15/2010	100	2.18
4/15/2010	2,000	2.18
4/15/2010	1,751	2.18
4/15/2010	100	2.18
4/15/2010	1,000	2.18
4/15/2010	271	2.18
4/15/2010	100	2.179
4/15/2010	100	2.179
4/15/2010	100	2.179
4/15/2010	100	2.18
4/15/2010	2,900	2.18
4/15/2010	700	2.18
4/15/2010	1,000	2.18
4/15/2010	1,000	2.18
4/15/2010	500	2.18
4/15/2010	200	2.18
4/15/2010	900	2.18
4/15/2010	12	2.18
4/15/2010	1,000	2.18
4/15/2010	1,000	2.18
4/15/2010	2,200	2.175
4/15/2010	4,000	2.18
4/15/2010	1,000	2.18
4/15/2010	100	2.18
4/15/2010	1,100	2.18
4/15/2010	3,000	2.18
4/15/2010	100	2.18
4/15/2010	200	2.18
4/15/2010	100	2.18
4/15/2010	100	2.18
4/15/2010	200	2.18
4/15/2010	1,700	2.18
4/15/2010	100	2.18
4/15/2010	200	2.18
4/15/2010	500	2.18
4/15/2010	1,000	2.18
4/15/2010	800	2.18
4/15/2010	289	2.18
4/15/2010	200	2.18
4/15/2010	4,000	2.18
4/15/2010	500	2.18
4/15/2010	2,500	2.18
4/15/2010	3,000	2.18
4/15/2010	200	2.18
4/15/2010	1,000	2.18
4/15/2010	1,000	2.18
4/15/2010	100	2.18
4/15/2010	500	2.18
4/15/2010	100	2.18
4/15/2010	1,800	2.18
4/15/2010	100	2.18
4/15/2010	2,000	2.18
4/15/2010	200	2.18
4/15/2010	200	2.18
4/15/2010	500	2.18
4/15/2010	1,100	2.18
4/15/2010	800	2.18
4/15/2010	200	2.18
4/15/2010	1,000	2.18
4/15/2010	177	2.18
4/15/2010	800	2.18
4/15/2010	243	2.18
4/15/2010	500	2.18
4/15/2010	943	2.18
4/15/2010	800	2.18
4/15/2010	100	2.18
4/15/2010	2,399	2.18
4/15/2010	600	2.18
4/15/2010	1,000	2.18
4/15/2010	1,000	2.18
4/15/2010	200	2.18
4/15/2010	700	2.179
4/15/2010	1,000	2.18
4/15/2010	1,000	2.18
4/15/2010	1,100	2.18
4/15/2010	1,000	2.18
4/15/2010	1,000	2.18
4/15/2010	200	2.18
4/15/2010	200	2.18
4/15/2010	100	2.175
4/15/2010	200	2.18
4/15/2010	2,500	2.18
4/15/2010	500	2.18
4/15/2010	549	2.18
4/15/2010	500	2.18
4/15/2010	200	2.18
4/15/2010	7,600	2.18
4/15/2010	24,600	2.18
4/15/2010	88	2.18
4/15/2010	900	2.18
4/15/2010	100	2.18
4/15/2010	18,700	2.18
4/15/2010	1,100	2.18
4/15/2010	2,000	2.18
4/15/2010	4,000	2.18
4/15/2010	1,000	2.18
4/15/2010	2,600	2.18
4/15/2010	1,000	2.18
4/15/2010	7,000	2.18
4/15/2010	2,000	2.18
4/15/2010	1,100	2.18
4/15/2010	1,500	2.18
4/15/2010	1,000	2.18
4/15/2010	2,600	2.18
4/15/2010	500	2.18
4/15/2010	100	2.18
4/15/2010	10	2.18
4/15/2010	100	2.18
4/15/2010	100	2.18
4/15/2010	1,500	2.18
4/15/2010	100	2.18
4/15/2010	1,000	2.18
4/15/2010	500	2.18
4/15/2010	390	2.18
4/15/2010	100	2.18
4/15/2010	13,000	2.18
4/15/2010	1,000	2.18
4/15/2010	359	2.18
4/15/2010	300	2.18
4/15/2010	200	2.18
4/15/2010	1,000	2.18
4/15/2010	441	2.18
4/15/2010	100	2.18
4/15/2010	2,500	2.18
4/15/2010	2,100	2.18
4/15/2010	100	2.18
4/15/2010	1,000	2.18
4/15/2010	500	2.18
4/15/2010	1,200	2.18
4/15/2010	2,000	2.18
4/15/2010	1,100	2.18
4/15/2010	1,000	2.18
4/15/2010	400	2.18
4/15/2010	900	2.18
4/15/2010	400	2.18
4/15/2010	1,000	2.18
4/15/2010	200	2.18
4/15/2010	1,900	2.18
4/15/2010	500	2.18
4/15/2010	1,000	2.18
4/15/2010	1,000	2.18
4/15/2010	800	2.18
4/15/2010	500	2.18
4/15/2010	198	2.18
4/15/2010	500	2.18
4/15/2010	500	2.18
4/15/2010	9,500	2.18
4/15/2010	2,702	2.18

Note: All of the above transactions in the Issuer’s Common Stock were effected by ICS Opportunities in the open market.

Javelin Pharmaceuticals (AMEX:JAV)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024

Javelin Pharmaceuticals (AMEX:JAV)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024